What Dabur Research Foundation does

Dabur Research Foundation (DRF) is a privately held preclinical Contract Research Organization headquartered in Ghaziabad, India, operating independently since a 2008 spin-off from Dabur India Ltd., where it had functioned as the group's R&D arm since 1979. DRF provides GLP-compliant preclinical biology services — In Vitro, Ex-Vivo, and In Vivo pharmacology studies, GLP toxicology, genotoxicology, DMPK and bioanalytical testing — across 16 therapeutic areas including oncology, immunopathology, metabolic disorders, neurology, dermatology, ophthalmology, and sexual health. The company runs a 75,000 sq ft integrated research campus with a 30,000 sq ft OECD GLP/AAALAC-compliant small-animal facility, 43 experimental rooms, and a cancer cell repository spanning 20 organ types, and reports 700+ GLP and 1,000+ non-GLP cumulative studies for clients globally.

The company's underlying platform is built on proprietary validated models, Quality-by-Design formulation development, advanced bioanalytical instrumentation, and a regulatory stack that includes OECD GLP, AAALAC, ISO 9001:2015, CPCSEA, DSIR SIRO, and a USFDA Test Facility registration (FEI 3006607414, 2024). Scientific leadership is anchored by 150+ scientists, including PhD-trained executives from NII and AIIMS, with a combined 200+ years of experience and 100+ international patents and 200+ publications to their credit. DRF complements these capabilities with a 2025-launched mobile app for client engagement and technical consulting services covering IND preparation, gap analysis, and project management.

Commercially, DRF operates a B2B professional services model with quote-based, project-specific pricing and no public rate card. It serves five primary segments — global pharmaceutical companies, global biotech companies, phytopharmaceuticals firms, cosmeceuticals companies, and academic institutions — across 50+ countries through direct enterprise sales, conference presence, and digital channels. The company emphasizes a "no conflict of interest" positioning (no in-house R&D in served therapeutic areas), strict sponsor confidentiality, and operational metrics of 98% on-time report delivery with over 80% delivered ahead of schedule.

Name

Dabur Research Foundation

Legal name

Dabur Research Foundation

Website

https://daburresearch.in

Company type

Private

Founded year

1979

Operating status

Operating

Headcount range

101–250 employees

Short description

Dabur Research Foundation is a privately held India-based preclinical CRO providing GLP-compliant in-vitro, ex-vivo, and in-vivo pharmacology, toxicology, DMPK, and bioanalytical services across 16 therapeutic areas to global pharmaceutical, biotech, cosmeceutical, and academic clients.

Ownership category

akta.pro rank

Product category

Preclinical Contract Research

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Medical Affairs, Scientific Communications & HEOR FSP (HLAGAOAG)

Keywords

• Preclinical contract research
• Drug discovery services
• GLP toxicology studies
• Pharmacokinetics testing
• Regulatory preclinical studies

Headquarters

HQ city

Ghaziabad

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Contract Research Organization (CRO) Services: Preclinical contract research services including discovery services (In Vitro, Ex-Vivo, In Vivo studies), regulatory services (toxicology, genotoxicology, DMPK, analytical), and technical consulting. Revenue generated through project-based contracts with pharmaceutical, biotech, cosmeceutical, and academic clients.
2. Regulatory Compliance Services: GLP-compliant studies, regulatory submissions support, and consulting for USFDA, EPA, EU, and other international regulatory requirements
3. Technical Consulting: Non-clinical overview, preclinical strategy recommendations, study design, and project management consulting services

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Dabur Research Foundation (DRF) is a Contract Research Organization offering preclinical contract research services including drug discovery (In Vitro, Ex-Vivo, and In Vivo pharmacology studies across 16 therapeutic areas), GLP-compliant toxicology and genotoxicology studies, DMPK and bioanalytical services, formulation development, and technical consulting. Services support IND-enabling studies and regulatory submissions for global pharmaceutical, biotech, cosmeceutical, and academic clients.

Product overview

Dabur Research Foundation (DRF) is a premier Indian Contract Research Organization (CRO) offering comprehensive preclinical services in drug discovery and development. Founded in 1979 and operating independently as a CRO since 2008, DRF provides integrated research solutions through three main service categories: Discovery Services (spanning 16 therapeutic areas including Oncology, Immunopathology, Metabolic Disorders, Neurology, Dermatology, and more), Regulatory Services (GLP Toxicology, Genotoxicology, DMPK, and Analytical/Bio-Analytical testing), and Other Services (Agrochemical testing, Formulation Development, Technical Consulting, and REACH registration). The company also offers a mobile application (DRF App) for client access. DRF serves global biotech, pharma, phytopharmaceuticals, cosmeceuticals, and academic sectors across 50+ countries.

Differentiator

Problem solved

Functional benefit

Products and services

• DRF App Mobile application for Android and iOS that provides enterprise clients with access to Dabur Research Foundation's CRO services and study management tools.
• Discovery Services - Therapeutic Area Research Comprehensive preclinical discovery services spanning 16 therapeutic areas (oncology, immunopathology, metabolic disorders, neurology, dermatology, women's health, sexual health, hair/scalp, anti-microbial/anti-viral, regenerative medicine, ophthalmology, cellular aging, etc.) using In Vitro, Ex-Vivo, and In Vivo models for global pharma and biotech clients.
• GLP Toxicology Services OECD GLP-compliant toxicology studies including acute, sub-acute, sub-chronic, chronic, and reproductive/developmental toxicity assessments for regulatory submissions.
• Genotoxicology Services Genetic toxicity testing including Ames test, chromosomal aberration, micronucleus test, and CHO cell gene mutation assays for regulatory submissions.
• DMPK Services Drug metabolism and pharmacokinetics services covering bioanalytical method development, pharmacokinetics, bioavailability, and drug-drug interaction studies using state-of-the-art instrumentation.
• Analytical & Bio-Analytical Services Analytical services including method development and validation, forced degradation studies, physicochemical testing, and pesticide residue analysis.
• In-Vitro Safety Testing Services Non-GLP and GLP safety testing including cytotoxicity, CFU-GM, skin irritation (RHE), and eye irritation (HET-CAM) assays.
• Agrochemical & CropCare Testing Services Agrochemical testing including acute oral toxicity, mutagenicity, and genotoxicology studies for pesticide registration with regulatory bodies such as EPA.
• Formulation Development Services Pharmaceutical formulation development using Quality-by-Design (QbD) approach with Design of Experiments (DOE) and risk assessment strategies for optimal dosage form development.
• Technical Consulting Services Regulatory and preclinical consulting including non-clinical overview, preclinical strategy recommendations, IND preparation, gap analysis, study design, and project management.
• REACH Registration Services EU REACH compliance support for chemical registration, evaluation, and authorization within the European Economic Area.

Quantifiable outcome

• 98% of reports delivered on time, with over 80% ahead of schedule
• +2 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• Oxford UniversitycoreStrategic or Co-development Partner · 1 January 2008Collaborative oncology research project initiated in 2008 focused on identifying and validating novel therapeutic targets. This partnership marked DRF's entry into global research collaborations and enhanced its scientific capabilities in cancer research.

Scale indicators8 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Piramal Pharma Solutions: India-based CRO/CDMO with preclinical and discovery services, including toxicology and bioanalytical capabilities — competes with DRF in serving global pharma/biotech with India-based research and GLP-certified facilities.
• Sai Life Sciences: India-based CRO/CDMO offering preclinical toxicology, DMPK, and integrated drug-discovery services — closely comparable to DRF in target customers, regulatory-grade infrastructure, and therapeutic-area breadth.
• Jubilant Biosys: India-based CRO offering integrated drug-discovery services including in vitro/in vivo pharmacology and DMPK — directly comparable to DRF in therapeutic-area coverage, target customer base, and India cost-arbitrage model.
• GVK Biosciences (now Aragen Life Sciences): India-headquartered CRO providing preclinical services, medicinal chemistry, and biology across multiple therapeutic areas — directly comparable to DRF in customer profile (global pharma/biotech), GLP-certified infrastructure, and India cost-arbitrage model.
• Syngene International: India-based integrated CRO/CDMO offering discovery, preclinical, and clinical research services to global pharma and biotech — most direct Indian competitor with overlapping therapeutic-area coverage and a comparable GLP-certified preclinical platform.
• Anthem Biosciences: India-based CRO/CDMO providing preclinical biology, DMPK, formulation development, and custom synthesis — direct competitor in the same India-discovery-CRO category, serving similar pharma and biotech clients with overlapping service lines.

Regional players

• Vimta Labs: India-based preclinical and clinical research services company with GLP-certified facilities — comparable to DRF in regulatory credentials and India-centric operations, though with a different mix leaning more toward clinical diagnostics and bioanalytical services.

Broad incumbents

• Charles River Laboratories: Global preclinical CRO leader offering GLP toxicology, in vivo pharmacology, and DMPK services across a much larger geographic and therapeutic footprint — a broad incumbent that DRF competes with for global pharma preclinical outsourcing.
• Eurofins Scientific: Global bioanalytical and preclinical testing services provider — competes with DRF in DMPK, bioanalytical, and GLP toxicology segments with a much larger international footprint and broader service catalog.
• WuXi AppTec: Global CRO/CDMO with extensive preclinical biology, toxicology, and DMPK capabilities across Asia — a broad incumbent that competes with DRF for global discovery and IND-enabling work, particularly in oncology and immunopathology.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/dabur-research-foundation/?viewAsMember=true
• Xx.com/contactdrf

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dabur Research Foundation